OR WAIT null SECS
Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.
Codexis, Inc., a developer of biocatalyst technology, and Porton Pharma Solutions, a custom intermediate and API developer and manufacturer, announced on April 23, 2018 a strategic collaboration in which Porton will license core elements of the Codexis biocatalyst technologies, including its proprietary biocatalyst libraries, high-throughput screening, and enzyme manufacturing knowledge for its global custom intermediate and API development and manufacturing business.
The partnership is designed to accelerate the creation and commercialization of low-cost, sustainable manufacturing processes, by using biocatalysts for the manufacture of small-molecule pharmaceuticals.
Porton will receive preferential access to the Codexis CodeEvolver protein engineering platform technology to create new biocatalytic process solutions, the press statement noted. Porton plans to install operations of these biocatalyst technologies into its custom contract development and manufacturing (CDMO) offerings.
Biocatalysts offer benefits of reduced costs, enhanced sustainability and improved product quality for small-molecule pharmaceuticals, the companies noted in a press statement. Previously Codexis earned three US EPA Presidential Green Chemistry Challenge awards for its biocatalysts’ contributions in these commercial-scale drug manufacturing innovations.